Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis

Martin Rübbelke, Dennis Fiegen, Margit Bauer, Florian Binder, James Hamilton, Jim King, Sven Thamm, Herbert Nar, and Markus Zeeb

*Medical Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany. Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany; Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT 06877; and Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany

As an alternative pathway of controlled cell death, necroptosis can be triggered by tumor necrosis factor via the kinases RIPK1/RIPK3 and the effector protein mixed-lineage kinase domain-like protein (MLKL). Upon activation, MLKL oligomerizes and integrates into the plasma membrane via its executioner domain. Here, we present the X-ray and NMR costructures of the human MLKL executioner domain covalently bound via Cys86 to a xanthine class inhibitor. The structures reveal that the compound stabilizes the interaction between the auto-inhibitory brace helix α6 and the four-helix bundle by stacking to Phe148. An NMR-based functional assay observing the conformation of this helix showed that the F148A mutant is unresponsive to the compound, providing further evidence for the importance of this interaction. Real-time and diffusion NMR studies demonstrate that xanthine derivatives inhibit MLKL oligomerization. Finally, we show that the other well-known MLKL inhibitor Necrosulfonamide, which also covalently modifies Cys86, must employ a different mode of action.

Necroptosis | drug discovery | NMR | X-ray

Controlled cell death is essential for tissue homeostasis. Besides the well-studied controlled cell-death mechanism apoptosis, other pathways of controlled cell death exist. One of the best-studied alternative mechanisms is Tumor Necrosis Factor (TNF)-induced necroptosis, which depends on TNF receptor 1, Receptor-Interacting Protein Kinase 1 (RIPK1), RIPK3, and the mixed-lineage kinase domain-like protein (MLKL). This TNF induces necroptosis when caspase activity is reduced (2). In contrast to apoptosis, necroptosis leads to the massive release of damage-associated molecular patterns, some of which have proinflammatory activity (3). Consequently, necroptosis has been associated with several inflammatory diseases, including amyo- tropic lateral sclerosis (4), chronic intestinal inflammation (5), and skin inflammation (6). Therefore, all three proteins involved in the canonical necroptosis signaling and execution cascade (RIPK1, RIPK3, and MLKL) are attractive molecular targets for therapeutic small-molecule intervention (7).

MLKL, the effector in the necroptosis signal chain, consists of two domains connected by two so-called brace helices, as described by Murphy et al. (8) for the mouse full-length protein. Structural information on human full-length MLKL is not available. However, individual domains could be characterized. The structure of the C-terminal domain of human MLKL was solved by X-ray crystallography (9) and reveals a catalytically inactive pseudokinase domain. Upon phosphorylation of the pseudokinase domain (Thr356 and Ser357) by RIPK3 (10), the activation signal is relayed to the N-terminal executioner domain. The solution structure of the latter has been solved by NMR spectroscopy by two laboratories (11, 12) and consists of a four-helix bundle (α1, α2, α3, and α5) as well as two additional α-helices (α4 and α6). The first brace helix (α6) plays an important role in the proposed plug-release mechanism (11). It postulates that phosphorylation of MLKL destabilizes the packing of the auto-inhibitory α-helix 6 to the four-helix bundle and, thereby, promotes the detachment of α-helix 6 from the four-helix bundle. The MLKL four-helix bundle is now able to oligomerize and integrates into the plasma membrane (13), which leads to permeabilization of the membrane and the breakdown of the cellular structure.

Inhibition of MLKL-induced pore formation can be achieved by different modes of action. First reports of successfully targeting the nucleotide-binding site of the pseudokinase domain (14) could not be confirmed as a specific MLKL-mediated effect due to additional effective inhibition of RIPK1 and RIPK3, which is most likely responsible for the observed antinecroptotic effect of that compound (15). Furthermore, compounds that are more selective for the MLKL pseudokinase nucleotide-binding site show no impact on necroptosis (15). In a cellular high-throughput screen (HTS) comprising ~200,000 compounds, two different chemical series of necroptosis inhibitors targeting the N-terminal four-helix bundle were discovered (10). The first inhibitor, Necrosulfonamide (NSA), binds covalently to Cys86 located in α-helix 4 of MLKL. Its optimization turned out to be challenging, due to steep structure–activity relationships (SARs) (10, 16). However, NSA is a widely used chemical probe. Compounds of the second class identified in the same HTS, the

Significance

Necroptosis is an emergency controlled cell-death mechanism, which only may be activated in case of impaired apoptosis. Necroptosis leads to unchecked release of proinflammatory cytoplasmatic content of the cells and is thereby implicated in disease. Two covalent inhibitor classes targeting the same cysteine of the necroptosis effector protein mixed-lineage kinase domain-like protein (MLKL) are reported. Here, we unravel the mode of action of the xanthine class of inhibitors that work by stabilizing the inactive state of MLKL by an essential π–π stacking interaction. The widely used covalent compound Necrosulfonamide (NSA) employs a distinct mode of action.

Author contributions: J.K., H.N., and M.Z. designed research; M.R., D.F., S.T., and M.Z. performed research; M.B., F.B., and J.H. contributed new reagents/analytic tools; M.R., D.F., S.T., and M.Z. analyzed data; and M.R. and M.Z. wrote the paper.

Competing interest statement: All authors, except J.K., were employees of Boehringer Ingelheim Pharma GmbH & Co. KG at the time this study was performed. J.K. is an employee of Boehringer Ingelheim Pharmaceuticals Inc.

This article is a PNAS Direct Submission. J.D.Y. is a guest editor invited by the Editorial Board.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

1To whom correspondence may be addressed. Email: markus.zeeb@boehringer-ingelheim.com.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2017406117/-/DCSupplemental.

First published December 14, 2020.
xanthines, also covalently modify Cys86. They show tractable SARs with the most potent compound revealing a half-maximal inhibitory concentration (IC50) of 2 nM in a cellular necroptosis assay (17).

Here, we present the high-resolution structures of the human MLKL executioner domain in complex with a covalent inhibitor of the xanthine class solved by X-ray crystallography and in solution by NMR spectroscopy. Both complex structures revealed a π–π stacking interaction between Phe148 and the xanthine core, which turned out to be the essential element of its inhibitory mode of action. Mutation analysis and an in vitro NMR functional assay were employed to investigate the inhibitory effects of the different small molecules supporting the finding that the xanthine class and NSA act via distinct mechanisms.

Results

To get a better understanding of the underlying mechanism of MLKL inhibition, we set out to determine the costructure between known inhibitors and the MLKL executioner domain. As a first step in the selection process of a suitable MLKL inhibitor for structural analysis, we confirmed the functional activity of published necroptosis inhibitors in two cellular assays. NSA binding mode was unsuccessful both in soaking and co-crystallization trials. Structural analysis by NMR spectroscopy was also hampered due to significant line broadening in fingerprint spectra (see $^1$H,15N-correlation spectrum in Fig. 6) and consecutively insufficient quality of nuclear Overhauser enhanced spectroscopy (NOESY) spectra (SI Appendix, Fig. S1). The xanthine class shows nanomolar IC50 values in cellular necroptosis assays in FADD-deficient Jurkat and U937 cells with a significantly better ratio between activity and toxicity (Table 1, Cpd 1+2 [Fig. 1]). Derivatives of Cpd 1 with modified less-reactive sulfoxide (Cpd 4 [Fig. 1]) or nonreactive sulfide (Cpd 5 [Fig. 1]) moieties showed reduced or no activity. Crystallization trials of Cpd 1 and the most active xanthine (Cpd 2) with the MLKL executioner domain did not yield suitable co-crystals amenable for X-ray crystallography. NMR measurements with Cpd 2 resulted in very well-dispersed fingerprint spectra with major chemical-shift perturbations (CSPs) (SI Appendix, Fig. S2 A and B). Backbone and side-chain assignments could be achieved by employing three-dimensional (3D) triple-resonance experiments, and nuclear Overhauser effect (NOE) spectra were collected to generate intraprotein distance restraints. Unfortunately, in 3D-filtered edited NOESY spectra, intermolecular cross-peaks could only be observed for the two methyl groups attached to the xanthine core, but not for the protons of the large substitution, including the phenyl ring (SI Appendix, Fig. S2C). A reliable costructure determination was therefore not possible. Thus, we synthesized several derivatives with similar potency in the cellular necroptosis assays. Among these, Cpd 3 (Fig. 1) proved to be more suitable for structural analysis by both X-ray crystallography and NMR spectroscopy.

Structures of the Complex of MLKL Executioner Domain and Cpd 3. First, we solved the structure of the unliganded MLKL executioner domain by X-ray crystallography (SI Appendix, Table S2) and NMR spectroscopy to have a basis for detailed analysis of structural changes induced by small-molecule binding. Both structures of the unliganded four-helix bundle were highly similar (rmsd value 2.1 Å) and showed only minor differences from the two published NMR solution structures [NMR structure has an rmsd of 2.4 Å to 2MSV (11) and an rmsd of 2.5 Å to 6D74 (12)] (SI Appendix, Fig. S3). The four-helix bundle was formed by α-helices 1, 2, 3, and 5 of MLKL with a short interjacent α-helix 4 on top. The flexible linker between α-helices 5 and 6 (residues 120 to 130) was not fully visible in the X-ray structures due to inherent flexibility. The subsequent α-helix 6 packed with multiple contacts, against the four-helix bundle (Fig. 2 A and D). The α-helix 6 were comparable to the helices forming the four-helix bundle, which indicated a rather rigid packing against the four-helix bundle. The calculated molecular correlation time ($\tau$ = 16 ns) for the rigid parts of MLKL was higher than expected for a spherical protein of its size (SI Appendix, Fig. S4). However, this may be explained by the elongated shape of MLKL, resulting in an anisotropic rotational diffusion. Interestingly, α-helix 6 showed a reduced molecular correlation time ($\tau$ = 12 ns), which also can be explained by the anisotropy, since helix 4 is oriented perpendicular to the four-helix bundle, and the N–H bond vectors therefore experience different molecular rotation.

Next, we determined the protein–ligand costructure with the newly synthesized xanthine Cpd 3 (Fig. 2). In filtered edited 3D NOESY NMR spectra, 41 intermolecular NOEs between MLKL and Cpd 3 (SI Appendix, Table S1 and Fig. S2C) could be assigned unambiguously and lead to a well-converged binding pose of the ligand in the structural NMR bundle (SI Appendix, Fig. S3). The binding pose of Cpd 3 was very similar in the NMR and the X-ray structures of the MLKL:Cpd 3 complex. Overall structural changes upon complex formation were minor, and the overall fold of MLKL was preserved. Backbone 15N NMR relaxation data of the complex were also very similar to unbound MLKL, and even the dynamics of the α-helix 4, where Cys86 is located, did not differ (SI Appendix, Fig. S4). The most profound structural change induced by covalent modification of Cys86 was the alteration of the conformation of Phe148 (arrows in Fig. 2 B and E). This resulted in a stacking interaction with the aromatic ring of the xanthine core, therefore creating an additional contact between α-helix 6 and the four-helix bundle. Minor differences between the NMR and X-ray costructure were most likely due to variations in construct lengths (residues 1 to 154 in the NMR and 1 to 150 in the X-ray structure, respectively). For example, intermolecular NOEs were detected from the Leu151 methyl groups to the ethylene glycol moiety, indicative of additional van der Waals contacts of Cpd 3 to the C-terminal brace helix (α-helix 6).

NMR-Based Analysis of Additional Compounds. Covalent binding of Cpd 1 and 2 to the MLKL executioner domain induced very similar changes in chemical shift observed in $^1$H,15N-correlation spectra compared to the binding of Cpd 3 (SI Appendix, Fig. S6), indicating that the binding mode of the three compounds is very similar. Nevertheless comparing the spectra of the MLKL executioner domain bound to Cpd 1, which is decorated with methyl

Fig. 1. Structural formulas of covalent MLKL inhibitors. Atoms in the xanthine core of Cpd 1 are numerated.
and no specific interaction holding it in place. Since there was plenty of room for the phenyl ring to move consistent with the observed lack of intermolecular NOEs being significant of the additional interaction between Trp133 and the backbone N–H correlation of Ala141 (12). The 1H,15N-correlation spectrum of the unliganded MLKL four-helix bundle showed only one peak for the His1–Nε1 correlation of Trp133 and the backbone N–H correlation of Ala141 (12). The 1H,15N-correlation spectrum of the unliganded MLKL four-helix bundle showed only one peak for the His1–Nε1 correlation of Trp133 (Fig. 3), consistent with its side chain packed between α-helices 2 and 5 and, thereby, anchoring α-helix 6 to the four-helix bundle. Adding 12 mM NM or 500 μM IP6 led to the appearance of a second very weak peak reporting on the detached α-helix 6 with a population of the activated state (p_{act}) of 1% and 4%, respectively (Fig. 3). Cpd 3 in contrast, did not induce the active state (Fig. 3). Combining 12 mM NM and 500 μM IP6 induced a dramatic increase of the population of the detached state (p_{det}) up to 86%). The additional peak reporting for the active state of Ala141 was also clearly visible and showed comparable results. Addition of 500 μM Cpd 3 shifted the population back to the auto-inhibited state of α-helix 6 (p_{act} = 19%), suggesting that the stabilization by the covalent modification protects MLKL from activation (Fig. 3). Comparable results were observed for two additional xanthine compounds (Cpd 1 and 2), for which an even less activated MLKL executioner domain was present after compound addition (Fig. 3C). Reducing the warhead reactivity (Cpd 4) or replacing it by a nonreactive moiety (Cpd 5) significantly reduced or abolished the inhibitory effect (Fig. 3C), which agrees very well with the results of the cellular necroptosis assay (Table 1). To further validate the importance of the π–π stacking interaction between the xanthine and Phe148 in α-helix 6, we carried out the functional NMR assay with the F148A-mutated variant of MLKL. The removal of the phenyl group induced significant CSPs localized in close proximity to the mutation site, due to the removal of ring currents and, therefore, strong electronic changes. The mutation did not alter the backbone secondary chemical shifts or 1H,15N-relaxation parameters significantly (SI Appendix, Fig. S8), indicating that MLKL F148A adopts a very similar overall structure with comparable backbone dynamics. The most pronounced difference was that residues comprising α-helix 4 in the wild-type (WT) protein showed line broadening to the point that corresponding peaks were not detectable in triple-resonance experiments, and, therefore, secure assignment and analysis of the secondary structure of these residues was not possible. MLKL F148A was more sensitive to the addition of 12 mM NM, 500 μM IP6, or the combination thereof. In the spectra in the presence of NM and the combination of NM and IP6, a third Trp133 peak appeared, most likely reporting on a state similar to the active state. The addition of Cpd 3 alone led to a small population of the active state (Fig. 3). In contrast to WT MLKL, addition of the xanthine compounds in the presence of 12 mM NM and 500 μM IP6 did not prevent the detachment of α-helix 6 from the four-helix bundle in the F148A mutant (p_{act} 90% for Cpd 3). The resulting activation is comparable to WT in the absence of Cpd 3 (Fig. 3). Thus, the stacking interaction of the xanthine core to Phe148 is vital for the inhibitory activity of these MLKL inhibitors.

Table 1. IC_{50} values for covalent MLKL inhibitors determined in cell-based necroptosis (NEC), apoptosis (APOP), or toxicity (TOX) assays in Jurkat and U937 cells.

|       | Jurkat NEC IC_{50}, nM | Jurkat TOX IC_{50}, nM | U937 NEC IC_{50}, nM | U937 APOP IC_{50}, nM | U937 TOX IC_{50}, nM |
|-------|------------------------|------------------------|----------------------|------------------------|----------------------|
| Cpd 1 | 574                    | 56,280                 | 312                  | >100,000               | >100,000             |
| Cpd 2 | 69                     | 3,835                  | 42                   | >100,000               | 4,375                |
| Cpd 3 | 541                    | 13,579                 | 271                  | >100,000               | 25,462               |
| Cpd 4 | 5,235                  | >100,000               | 3,167                | >100,000               | >100,000             |
| Cpd 5 | >100,000               | >100,000               | >100,000             | >100,000               | >100,000             |
| NSA   | 1,399                  | 6,197                  | 454                  | >100,000               | 14,694               |

Fig. 2. (A–C) Superimposition of the X-ray structures of unliganded MLKL executioner domain (gray; PDB ID code 6ZVO) and covalently bound to Cpd 3 (orange; PDB ID code 6Z2I). (D–F) Superposition of the NMR structures of unliganded MLKL executioner domain (gray; PDB ID code 6ZL2) and covalently bound Cpd 3 (blue; PDB ID code 6Z9P). The compound is presented as sticks and colored in green. Key interacting residues are shown as sticks. The conformational change of Phe148 located in the autoinhibitory α-helix 6 is indicated by arrows. N and C termini are indicated.
Xanthines Decelerate Oligomerization of the MLKL Executioner Domain. While MLKL was stable in the presence of either 500 μM IP6 or 12 mM NM (SI Appendix, Fig. S13), dispersed peaks were disappearing over time in the presence of the combination of the two. Monitoring this decay by real-time NMR, a series of $^1$H,$^15$N-correlation spectra were recorded in the presence of 12 mM NM and 50 μM IP6. The latter concentration was reduced to slow down the process to enable real-time NMR detection, because at 500 μM IP6 concentration, 86% activation could be observed in the functional assay in the $^1$H,$^15$N-correlation spectrum measured directly after sample preparation. The loss of peak intensity can be fitted with a biexponential decay with a fast time constant ($T_1$) of 0.35 ± 0.07 h and a slow time constant ($T_2$) of 10.0 ± 1.0 h. The time constants were comparable for all six α-helices of MLKL, indicating a simultaneous cooperative conformational change or transition to an oligomeric state of the protein (Fig. 4 C and D and SI Appendix, Table S3). In addition to the known peaks reporting on the active state with α-helix 6 being detached (Ala141 N,H and Trp133 N,H), peaks in the random coil region of the spectrum appeared (Fig. 4A). At the end of the time course, much fewer peaks were present in the spectrum compared to the guanidinium chloride-induced fully unfolded MLKL (SI Appendix, Fig. S9A), suggesting that only a small part of the protein was unfolded and remained detectable. Backbone assignment of these peaks revealed that they belonged to residues 129 to 154, comprising the residues of α-helix 6 in the native inactive state (SI Appendix, Fig. S9B). Secondary chemical shifts confirmed that α-helix 6 becomes largely unfolded and has, according to $^15$N-relaxation data, increased mobility ($\tau_C = 10$ ns) and reduced rigidity (heteronuclear NOE around zero) in the activated state (SI Appendix, Fig. S10). Only residues 142 to 147 showed small positive secondary chemical shifts, slightly less reduced $\tau_C$ values, and lower heteronuclear NOEs, indicating a small α-helical propensity. The uniform disappearance of the dispersed peaks of the four-helix bundle in $^1$H,$^15$N correlation spectra points toward an oligomerization or aggregation of the four-helix bundle in the presence of IP6 and NM, while the high flexibility of the now-unfolded α-helix 6 indicates that it tumbles freely in solution. To characterize the secondary structure of the NMR invisible oligomerized state, far-ultraviolet circular dichroism (CD) spectra of the MLKL executioner domain were recorded, which showed the characteristic pattern of an α-helical protein (SI Appendix, Fig. S11). The slightly reduced molar ellipticity compared to monomeric MLKL can be attributed to the unfolding of α-helix 6.

Since the xanthine compounds were able to keep the MLKL executioner domain in the inactive state, a time course in the presence of 50 μM IP6, 12 mM NM, and 500 μM Cpd 3 was recorded. Under these conditions, a significantly decelerated decay of the dispersed signals was observed. After 48 h, these signals decayed only to ∼70% intensity. Cross-peaks reporting on
the unfolded, detached α-helix 6 likewise appeared more slowly in the presence of Cpd 3 (Fig. 4 B–D).

**Xanthines Keep the MLKL Executioner Domain in a Monomeric State.**

To further characterize the oligomerized MLKL executioner domain, NMR diffusion experiments were conducted directly succeeding the end of the real-time NMR series (orange dots in Fig. 5A). This was compared with a fresh sample of unliganded MLKL executioner domain (black dots in Fig. 5A). The unliganded MLKL executioner domain had a hydrodynamic radius of 19 Å (Fig. 5B), which is consistent with a monomer. In contrast, the oligomerized MLKL executioner domain under the influence of 12 mM NM and 50 μM IP6 had a strongly increased hydrodynamic radius of 60 Å, which indicates oligomerization. The NMR diffusion experiments show that the hydrodynamic radius of the MLKL executioner domain in complex with Cpd 3 in the presence of NM and IP6 was 30 Å and, therefore, 30 Å smaller than in the absence of Cpd 3. Taken together, the NMR data suggest that the xanthine class of compounds slows oligomerization of the MLKL executioner domain by keeping the protein in the inactive, α-helix 6 attached monomeric conformational state.

In a next step, we conducted NMR diffusion experiments with NM concentrations above and below the critical micelle concentration of 6 mM, to find out if the increased hydrodynamic radius of the MLKL executioner domain is dependent on the presence of micelles. NM dissolved in buffer without protein had a higher hydrodynamic radius at 12 mM than at 3 mM, indicating the formation of micelles at higher NM concentrations. The presence of 500 μM IP6 and 500 μM Cpd 3 had no influence on the hydrodynamic radius of NM (SI Appendix, Fig. S12). While the MLKL executioner domain displayed a hydrodynamic radius of 57 Å in the presence of 500 μM IP6 and NM micelles (12 mM) after about 2 d of incubation, it stayed monomeric in the absence of micelles (3 mM NM) (Fig. 5C). Therefore, the oligomerization depends on micelles, and the observed species is most likely a micelle-integrated oligomeric MLKL executioner domain. In the presence of NM micelles (12 mM NM) and 500 μM IP6, after 2 d of incubation, a stronger protective effect of 500 μM Cpd 3 was observed compared to the NMR time course with only 50 μM IP6 present, resulting in a completely monomeric MLKL executioner domain. The differences between the experiments with substoichiometric IP6 concentration (50 μM) and excess of IP6 (500 μM) in the presence of the compound can probably be explained by unspecific aggregation in the substoichiometric case, which led to an apparent higher hydrodynamic radius of the inhibited MLKL.

**NSA Employ a Different Mode of Action.**

Besides the xanthine class, we also investigated NSA, the first identified MLKL inhibitor, which also covalently modifies Cys86, and addressed the question of if NSA is able to prevent the detachment of α-helix 6 in the presence of NM and IP6. In contrast to the xanthine class, NSA induced no CSP, but, rather, significant and specific line broadening of the MLKL executioner domain cross-peaks in the 1H,15N-correlation spectrum (Fig. 6). The residues Tyr23, Cys24, Lys26, Gln27, Ile-85, Thr90, Ala91, and Leu97 showed strong line broadening with peak intensities smaller than 20% of the unliganded protein. These and additional residues in α-helices 2, 4, and 6 experienced a line-broadening cluster around Cys86, indicating a flexible binding pose of NSA. This is supported by the observation that only a few intermolecular NOEś (consistent to originate from residues Leu89 and Thr90) could be detected (SI Appendix, Fig. S1). It suggests that the covalent bond anchors the inhibitor to Cys86, and the remaining parts hardly interact with the MLKL executioner domain. To further address the inhibitory mechanism of NSA, we performed the NMR-based functional assay. The signature cross-peak of Trp133 H1α–N1ε showed no CSP upon binding of NSA to the executioner domain, indicating that α-helix 6 remains in the attached auto-inhibitory state. Addition of 12 mM NM and 500 μM IP6 to the MLKL:NSA complex led to a complete population shift to the active α-helix detached state. Hence, NSA is not able to prevent the detachment of the brace α-helix 6 under these conditions.
conditions, and, therefore NSA must have a different mechanism of action compared to the xanthine class of inhibitors.

Discussion

MLKL is a key player in the necroptosis pathway, encompassing a C-terminal regulatory and an N-terminal executioner domain. It gets activated through phosphorylation of Thr357 and Ser358 by RIP3 kinase (10) and subsequently oligomerizes via its executioner domain and inserts into the membrane (12, 18). The auto-inhibitory role of α-helix 6 has been demonstrated by mutations of anchoring residues Trp133 and Asp137 that weaken the packing of α-helix 6 to the four-helix bundle and increase its activity in necroptosis (12). Furthermore, the addition of IP6 and the detergent NM leads to detachment of the auto-inhibitory α-helix 6, its unfolding, and oligomerization of the four-helix bundle, which is a requirement for its membrane association (19). Here, we demonstrate that the process of oligomerization already takes place with substoichiometric amounts of IP6 (50 μM IP6 and 300 μM MLKL executioner domain) and can be described by a biexponential fit with a fast (0.35 h) and a slow (10.0 h) time constant. Furthermore, we demonstrate that the first brace helix (α-helix 6) unfolds and gets highly flexible under these conditions, which matches findings by Quarato et al. (19). In NMR diffusion experiments, we find that the oligomerization of the MLKL executioner domain in response to NM and IP6 is dependent on the presence of micelles. While the MLKL executioner domain stays monomeric in the presence of IP6 and NM below the critical micelle concentration, the hydrodynamic

Fig. 5. (A) Integral of amide region in 15N-edited NMR diffusion experiments plotted against the used gradient strength. Black dots depict data for the MLKL unliganded executioner domain. Orange dots depict data for the protein in the presence of 12 mM NM and 50 μM IP6, and blue dots data for the protein in the presence of 12 mM NM, 50 μM IP6, and 500 μM Cpd 3 collected succeeding the time course presented in Fig. 4. (B) Hydrodynamic radii for the MLKL executioner domain extracted from 15N-edited NMR diffusion experiments (raw data partly depicted in A) under the influence of NM, IP6, and Cpd 3. The NM concentration is given in millimolar. Presence of 500 μM IP6 and 500 μM Cpd 3 is indicated by plus signs. (C) Hydrodynamic radii for the MLKL executioner domain under indicated conditions extracted from regular, not filtered, NMR diffusion experiments. The NM concentration is given in millimolar. The presence of 500 μM IP6 or 500 μM Cpd 3 is indicated by plus signs.

Fig. 6. (A) NMR 1H,15N-correlation spectrum of 80 μM unliganded MLKL executioner domain (black), in complex with NSA (red) at a concentration of 200 μM, which is sufficient to saturate the protein, and additionally in the presence of 12 mM NM and 500 μM IP6 (blue). (B) Ratio of the peak intensities of the MLKL executioner domain/NSA complex over the unliganded protein extracted from spectra shown in A. (C) NMR structure of the MLKL executioner domain. Spheres indicate residues for which the peak height in the unliganded and the NSA bound state could be compared. Salmon spheres indicate residues that have peak intensities smaller than 40%, and red spheres residues with peak intensities smaller than 20% in the NSA bound state. (D) Regions of the spectrum the 1H,15N-correlation spectra containing the Trp133 Ni−1:Hi:1 cross-peaks in the auto-inhibited state where α-helix 6 is attached to the four-helix bundle (inact. state) and in the active state where it is detached (act. state).
radius increases drastically in the presence of IP6 and NM above the critical micelle concentration. Furthermore, we demonstrate that the oligomerized form of MLKL stays α-helical. MLKL has been reported to form trimers (20), tetramers (21), or octamers (22) as active components that integrate into the membrane. The theoretical hydrodynamic radii of a trimer, tetramer, and an octamer of the executioner domain can be estimated by an empirical formula postulated by Wilkins et al. (23) to be 25, 31, and 38 Å, respectively, while two octamers would have an estimated hydrodynamic radius of 46 Å. The contribution of the micelle is difficult to estimate, since it might change size upon MLKL integration. We observe a hydrodynamic radius for the MLKL executioner domain in the presence of NM micelles of 60 Å in NMR diffusion experiments. This high hydrodynamic radius of the MLKL executioner domain in our diffusion experiments can only be explained by more than one higher-order oligomer (e.g., tetramers or octamers) integrated into the micelle. A better estimation of the oligomeric state of the MLKL executioner domain is hampered by the lack of structural information of MLKL inserted into micelles or the plasma membrane.

Necroptosis could, in principle, be inhibited either by tackling the pseudokinase domain or the executioner domain of MLKL (7). Currently, two classes of compounds are reported to inhibit MLKL by covalently binding to Cys86 in the short α-helix 4 located on top of the four-helix bundle, which comprises α-helices 1, 2, 3, and 5. Here, we report that the xanthine class of inhibitors acts by stabilizing the packing of α-helix 6 against the four-helix bundle through the formation of a stabilizing π–π-stacking interaction between Phe148 located in α-helix 6 and the xanthine core. Destabilization of packing of α-helix 6 against the four-helix bundle leads to more active MLKL in necroptosis. This was shown previously by using mutagenesis of the anchoring residue D137 (12). Conversely, stabilizing the packing of the auto-inhibitory α-helix 6 against the four-helix bundle by additional contacts provided by the compound is therefore a viable mode of action for MLKL necroptosis inhibitors. The stronger interaction decelerates oligomerization of the executioner domain and its integration into micelles, as shown here by real-time NMR and NMR diffusion experiments. Mutation of Phe148 to alanine leads to loss of the stabilization of the auto-inhibited state of MLKL by xanthine class compounds, confirming the key role of the π–π-stacking interaction for the activity of the xanthine class. The importance of the covalent mode of action of the xanthine class is demonstrated by the partial or complete inactivity of xanthine compounds with less or nonreactive sulfoxide or sulfide warheads, instead of the highly reactive sulfone warhead in cellular assays and the functional NMR assay. This is in agreement with findings that activity of compound Cpd 1 and Cpd 2 is hampered in MLKL knockout cells transfected with C86S-mutated MLKL (17).

This specificity to Cys86 was not demonstrated explicitly for Cpd 3. However, due to the high structural similarity to Cpd 1 and Cpd 2, the virtually identical behavior in the NMR functional assay, and the covalent binding to Cys86 observed in the complex structures, we assume that the inhibitory effect of Cpd 3 in cells originates solely from covalent binding to Cys86 of MLKL.

The other well-known inhibitor NSA, which also binds covalently to Cys86, is not able to stabilize the interaction between α-helix 6 and the four-helix bundle in the context of the MLKL executioner domain, as shown by the NMR functional assay. NSA therefore seems to work independently of the auto-inhibitory first brace helix. In contrast to the xanthine class of compounds that introduces well-defined changes in chemical shift in 1H, 15N NMR correlation spectra upon binding to Cys86, NSA instead induces severe line broadening of peaks corresponding to residues proximal to the covalent modification site. In addition, only a few weak intermolecular NOE cross-peaks could be detected, indicating that NSA does not have a well-defined binding pose in the context of the N-terminal executioner domain alone. Using molecular-dynamics simulations with a full-length model of human MLKL with covalently bound NSA, Bansal et al. (24) show that NSA is able to lock the domain–domain orientation between the four-helix bundle and the pseudokinase domain in an inactive orientation. According to the molecular-dynamics simulations, NSA forms, besides the covalent bond to Cys86, a π-cation interaction with Lys157, which is located in the second brace helix subsequent to α-helix 6. Furthermore, displacement of Lys157 by NSA leads to the formation of several new interactions between the pseudokinase domain, the brace helix, and the four-helix bundle. In contrast to the stabilization of the packing of α-helix 6 against the four-helix bundle observed for the xanthine compounds, the simulation predicts that NSA reduces the α-helical content of the brace helices (24). The proposed mechanism for the activity of NSA fits well with the observed lack of a rigid binding pose in the context of the MLKL executioner domain, since the construct used for the structures and NMR measurements comprises the four-helix bundle, including the first brace helix (α-helix 6), which lacks most of the proposed interaction sites of NSA. In a similar fashion, the phenyl group of Cpd 2, the xanthine with the highest cellular activity, might make additional contacts to the second brace helix or the pseudokinase domain in the context of full-length MLKL. We cannot observe any NOE signals to this part of Cpd 2, since when bound to the N-terminal executioner domain, it probably moves freely in the solvent.

In contrast to the regular full-length MLKL1, MLKL exists in a second isoform (MLKL2) that is generated by alternative splicing. MLKL2 contains the executioner domain, the two brace helices, and the C terminus of MLKL, but lacks most of the regulatory pseudokinase domain. MLKL2 is more active than MLKL1 in triggering necroptosis in cellular assays (25), but should be amenable to inhibition by the xanthine class, since all relevant residues are included in the shorter isoform.

In conclusion, we find that the two known classes of MLKL inhibitors, NSA and the xanthine class, have different modes of action, even though they both bind covalently to Cys86 within the N-terminal executioner domain. While NSA is reported to lock the executioner and the pseudokinase domain in an inactive domain–domain orientation, the xanthine class strengthens the inhibitory effect of α-helix 6 by introducing the essential π–π stacking to Phe148.

Materials and Methods

Cellular Assay. For the Jurkat FADD+/− Necroptosis assay, compounds were serially diluted in 100% dimethyl sulfoxide (DMSO) (Sigma-Aldrich catalog no. 41641), and 250 nL was transferred to a sterile 384-well microtiter plate (PerkinElmer catalog no. 6007688) via Echo liquid handler (LABCYTE). Five thousand Jurkat FADD−/− cells (ATCC catalog no. CRL-2572) in 20 μL of modified Roswell Park Memorial Institute medium (Gibco catalog no. 10491), 10% fetal calf serum (Gibco catalog no. 10099), 1x Anti/anti (Gibco catalog no. 15240-062), 1x L-Glutamax (Gibco catalog no. 35050-087), and 1% PenStrep (SIGMA catalog no. P4333) were seeded into each well of the prepared assay plate with compound. Cells and compounds were incubated for 30 min at 37 °C (humidified incubator with 5% CO2). After incubation, 5 μL of recombinant human TNFα (huTNFα) (Biotrend catalog no. cyt-223; 10 ng/mL final concentration [f.c.]) was added to the cells, followed by an incubation of 24 h at 37 °C. Following the incubation, the experimental plates were equilibrated to room temperature (30 min) before 25 μL of Cell Titer Glo Luminescent Cell Viability Assay System reagent (Promega catalog no. G7571) was added to the plate wells, incubated at room temperature for ~10 min. After incubation, the samples were analyzed for luminescence by using an Envision reader (PerkinElmer).

Each assay plate contained wells with "high" and "low" controls. High controls (100% CTL) were defined as cells treated with DMSO, and low controls (0% CTL) were defined as cells treated with 10 ng/mL recombinant huTNFα. IC50 values were calculated based on the percentage of control values using a four-parameter-fitting model.
MLKL antagonists were also evaluated in a necrosis assay with U937 cells (26) (ATCC catalog no. CRL-1593.2). The assay procedure with U937 cells was as described for the Jurkat FADD−/− necrosis assay with the following modifications: 8,000 cells were seeded per well, and, in addition to the recombinant huTNFα, cells were also incubated in the presence of 10 μM (f.c.) carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone (ZVAD-fmk) (Enzo Life Sciences catalog no. ALX-260-020). Low controls (0% CTL) were defined as cells treated with 100 ng/mL recombinant huTNFα plus 10 μM ZVAD-fmk.

Furthermore, MLKL antagonists were tested in a U937 apoptosis assay in the presence of 3 μM (f.c.) NSA (Tocris catalog no. 5025) and 100 ng/mL (f.c.) recombinant huTNFα in the same way as described for the U937 necrosis assay. Low controls (0% CTL) were defined as cells treated with 100 ng/mL recombinant huTNFα plus 3 μM NSA.

MLKL antagonists were tested in cytokine assays by using Jurkat FADD−/− and U937 cells according to the assay procedures described for the necrosis assays, but without treatment with recombinant huTNFα and/or ZVAD-fmk. High controls (100% CTL, no effect) were defined as cells treated with DMSO, and low controls (0% CTL) were defined as medium without cells (0% CTL, maximal effect).

All cellular assays were done for Cpd 1, Cpd 2, Cpd 3, Cpd 4, and Cpd 5 in duplicate and in quadruplicate for NSA.

Chemical Synthesis of Compounds. Cpd 1, 2, 4, and 5 were prepared according to the literature (17). NSA was prepared according to the literature (16). Cpd 3 was synthesized as follows: To a stirred solution of 8-Methanesulfonyl-1,3,6,7,9-decahydropyrimido[4,5-d]pyrimidine ((H2)pyrimine-2-carboxylic acid (27) (35 mg, 0.14 mmol, 1 equivalent [equiv]) in dimethylformamide (2 mL) was added potassium carbonate (37.5 mg, 0.27 mmol, 2 equiv) and 2-methoxycarbonyl methyl chloride (17 μL, 0.15 mmol, 1.1 equiv). After being stirred for 2 h at ambient temperature, the reaction mixture was treated with H2O and directly purified via high-performance liquid chromatography (HPLC) (XbridgeC18, MeCN/H2O/NH3) to afford Cpd 3 (33 mg) in 80 to 90% liquid chromatography purity, with a 1:1 mixture of the protein solution and a reservoir solution and incubated at 4 °C.

The expression of the MLKL executioner domain for X-ray crystallography was synthetized as follows: To a stirred solution of 8-Methanesulfonyl-1,3,6,7,9-decahydropyrimido[4,5-d]pyrimidine ((H2)pyrimine-2-carboxylic acid (27) (35 mg, 0.14 mmol, 1 equivalent [equiv]) in dimethylformamide (2 mL) was added potassium carbonate (37.5 mg, 0.27 mmol, 2 equiv) and 2-methoxycarbonyl methyl chloride (17 μL, 0.15 mmol, 1.1 equiv). After being stirred for 2 h at ambient temperature, the reaction mixture was treated with H2O and directly purified via high-performance liquid chromatography (HPLC) (XbridgeC18, MeCN/H2O/NH3) to afford pure Cpd 3 as colorless wax (10.3 mg, 22%). 1H NMR (400 MHz, d5-DMSO) δ 6.03 (s, 2H), 3.71 to 3.67 (m, 2H), 3.50 (s, 3H), 3.46 (s, 3H), 3.43 to 3.39 (m, 2H), 3.27 (s, 3H), 3.18 (s, 3H); mass spectrometry (positive electrospray ionization): m/z calculated for C21H19N2O5S [M+H]+ 347.1020, found 347.040.

Furthermore, MLKL antagonists were tested in a U937 apoptosis assay in the presence of 3 μM (f.c.) NSA (Tocris catalog no. 5025) and 100 ng/mL (f.c.) recombinant huTNFα in the same way as described for the U937 necrosis assay. Low controls (0% CTL) were defined as cells treated with DMSO, and low controls (0% CTL) were defined as medium without cells (0% CTL, maximal effect).

Crystals were frozen in liquid nitrogen directly from mother liquor. Data were collected at the Swiss Light Source (SLS) beamline X10SA (Paul Scherrer Institute) using the PILATUS 6M-F detector. MLKL antagonists belonged to space group P21, and contained three monomers per asymmetric unit. Liganded crystals adopted space group P43 with two monomers per asymmetric unit. Due to a strong local symmetry between the two molecules in the asymmetric unit, diffraction data merging in 4mm resulted in very good statistics as well. Images were processed with XDS (28) and autoPROC (29). The resolution limits were set by using default autoPROC settings. The structures were solved by molecular replacement using MOLREP (30), Phaser (31), DIMELE (32), and Protein Data Bank (PDB) ID code 4BTF (8) or the unliganded structure as a start model. Subsequent model building and refinement was done by using standard protocols using CCP4 (32) programs, Coot (33), Phenix (34), and autoBuster (35). A summary of the statistics can be found in SI Appendix, Table S2. Figures showing structures were made with the PyMOL software.

Structure Determination by NMR Spectroscopy. All NOEY experiments for structure calculation were recorded on a Bruker Avance III 800-MHz NMR spectrometer equipped with a TCI cryogenic probe in 2.5-mm NMR tubes at 298 K. Assignment experiments were either recorded on the same spectrometer or on an Avance III HD 600-MHz NMR spectrometer equipped with a QCI cryogenic probe. Two samples were necessary for each of the structure calculations (24). For the MLKL N-terminal executioner domain, one in a 20 mM sodium phosphate buffer at pH 7.5 containing 150 mM sodium chloride and 5 mM deuterated DTT and one in the same buffer, but with D2O instead of H2O and an adjusted pH of 7.1 to compensate for the isotope effect of deuterium. For the MLKL N-terminal executioner domain, unliganded structure protein concentrations of 430 μM (D2O buffer) and 400 μM (H2O buffer) were used. In the case of the MLKL:Cpd 3 complex, 340 μM (H2O buffer) and 385 μM (D2O buffer) protein and 1,200 μM and 840 μM Cpd 3 were mixed. It was checked with 1H,13C-correlation spectra if MLKL was completely occupied with Cpd 3. For the assignment of the backbone and side-chain resonances of the MLKL N-terminal executioner domain, the published assignments from Su et al. (11) (Biological Magnetic Resonance Data Bank code 2Z135) were used as a starting point. Assignments were confirmed for the unliganded protein and transferred to the MLKL:Cpd 3 complex by using triple-resonance experiments (HNCACB, CBCA(CO)NH, HNCC TOCSY, HCCCH TOCSY, and HCCCH TOCSY) (36). Chemical-shift referencing was done directly for 1H and indirectly for 13C and 15N by using the methyl group signals of sodium trimethylsiliconpropanesulfonate (37). Distance restraints were derived from 15N-edited NOEY (H2O buffer) and two separate 13C-edited NOEY spectra for the aliphatic and aromatic carbon-bound protons. The NOEY mixing time was set to 120 ms. For the complex, an additional two filtered 13C-edited NOEY spectra (38) separate for the aliphatic and aromatic carbon-bound protons were recorded with a mixing time of 200 ms to identify intermolecular NOEs. The spectra were processed by using the software Topspin 3.5 (Bruker Biospin) and analyzed by using CcpNmr analysis (39). Torsion angle restraints were calculated from chemical shifts by the software CYANA (40). The structures were performed with the software CYANA (41). The error margins for the proton chemical shifts were set to 0.05 parts per million (ppm) and for the heteronuclear chemical shifts to 0.5 ppm. In the final structure calculation, 100 structures were calculated, from which the 20 lowest-energy structures were selected for the NMR structure bundle. Figures showing structures were made with the PyMOL software.

NMR Relaxation Experiments. All relaxation experiments were recorded on Bruker Avance III HD 600-MHz NMR spectrometer equipped with a QCI cryogenic probe in 2.5-mm NMR tubes at 298 K. Either 300 μM WT MLKL or 150 μM F148A-mutated MLKL was used in a 20 mM sodium phosphate buffer at pH 7.5 containing 150 mM sodium chloride and 5 mM DTT. The WT protein was measured unliganded, in the presence of 1.2 mM Cpd 3 and in the presence of 12 mM MM and 500 μM IP6. For determination of T1, T2 relaxation delays, including two duplicates between 10 ms and 2 s, were recorded. Each spectrum was recorded with 128 complex points in the indirect dimension, an interscan delay of 2 s, and 16 scans. Exchange-free T2 time constants were calculated from T1 and T2 time constants. The heteronuclear NOE was recorded in an interleaved experiment with 128 complex points per spectrum, an interscan delay of 2 s,
and 16 scans. For the F148A sample, all experiments were run with doubled scans. Peak integration for nonoverlapping peaks and fitting of relaxation data were done with CcpNmr analysis (39). The fitting error is reported in the error bars for $T_2$ for $T_2^*$ and $T_1$, error propagation based on the fitting error of $T_2$ and $T_1$ was performed.

**Functional NMR Assay.** For the functional NMR assay $^1$H, $^15$N-correlation spectra were recorded on a Bruker Avance III HD 600-MHz NMR spectrometer equipped with a cryogenic QCI probe in 2.5-mm NMR tubes at 298 K. Spectra were recorded with 64 complex points in the indirect dimension, 96 scans, and an interscan delay of 2 s. For the samples, 80 μM MLKL N-terminal executioner domain (residues 1 to 154) was used in a 20 mM sodium phosphate buffer at pH 7.5 containing 150 mM sodium chloride and 1 mM TCEP. For the different conditions, either 500 μM IP6, 12 mM NM, or a combination of the two were used. The xanthine compounds were tested at 500 μM, while NSA, due to limited solubility, was tested only at 200 μM, which is sufficient to saturate MLKL. Spectra were analyzed, and peaks were integrated in CcpNnmr analysis (39). The population of the α-helix 6 attached state was calculated by using the integral of Trp133 Hε cross-peak and the intensity of the Trp133 Hε cross-peak of the invariant state in the proton (H) and nitrogen (N) dimension.

**Real-Time NMR.** For the real-time NMR measurements, 300 μM MLKL (1 to 154) in 20 mM sodium phosphate buffer at pH 7.5 containing 150 mM sodium chloride and 1 mM TCEP was used to record a series of $^1$H,$^15$N-correlation spectra with a measurement time of 20 min each for 2 d. Spectra were processed using Topspin 3.5, and peaks were integrated by using CcpNmr analysis (39). The peak intensity of selected peaks was plotted against the elapsed time, and the curve time was fitted according to Eq. 2.

$$y = A \cdot \exp(-(B \cdot x)) + C \cdot \exp(-(D \cdot x)) + E,$$

where $B$ and $D$ are the rates of the biexponential decay, and time constants $T_2$ and $T_1$ were derived by calculating the reciprocal value $1/B$ and $1/D$, respectively.

**NMR Diffusion.** NMR diffusion experiments were recorded as pseudo two-dimensional experiments with varying gradient strength either as a $^1$H-filtered NMR experiment (42) (recorded with $^1$H-labeled protein). For $^1$H-one-dimensional ($^1$H-1D) diffusion experiments (using unlabeled protein), a stimulated echo sequence with a longitudinal eddy current delay was employed using bipolar gradient pulses for diffusion (43) was employed. Water suppression was achieved by a WATERGATE w5 pulse scheme (44). The diffusion time was 80 ms, except for the regular $^1$H-1D experiment for the condition with concentrations of 12 mM and 500 μM without compound, where 200 ms were used, to determine the significantly smaller diffusion constant and, therefore, larger hydrodynamic radius more accurately. In either case, 300 μM MLKL (1 to 154) in 20 mM sodium phosphate buffer at pH 7.5 containing 150 mM sodium chloride and 1 mM TCEP was used. For the $^1$H-1D experiments, dioxane was added as an internal standard to calculate the hydrodynamic radius. For the $^1$H-filtered experiment, the diffusion constant of dioxane from a $^1$H-1D experiment under equivalent conditions was used. Eq. 3 was used for the fitting of a diffusion constant of not-overlapped signals like the protein amide region.

$$y = A \cdot \exp(-(d \cdot x)),$$

where $d$ is the diffusion constant. For overlapped peaks, a sum of two or three of the terms in Eq. 2 was used, where the diffusion constants of known components were kept constant. The hydrodynamic radius was calculated by using the determined diffusion constants of the component of interest (d) and dioxane (dioxane) and the known hydrodynamic radius of dioxane (2.12 Å) (23) using Eq. 4.

$$r_H = 2.12A \cdot \frac{d \text{dioxane}}{d},$$

where $r_H$ is the hydrodynamic radius of the component of interest.

**CD Spectroscopy.** CD spectra were recorded on a JASCO J-715 CD spectrometer in a 0.05-cm-path-length cuvette. A concentration of 0.5 mg/mL $^1$N-labeled MLKL executioner domain was measured in a 20 mM sodium phosphate buffer at pH 7.5 containing 150 mM sodium chloride and 0.5 mM TCEP immediately after mixing and in the presence of 12 mM NM and 500 μM IP6 after an incubation period of 4 d. After CD measurement, the activation state of MLKL was confirmed by recording a $^1$H,$^15$N-correlation NMR spectrum.

**Data Availability.** Structural information data have been deposited in the PDB (PDB ID codes 6ZVO, 6Z21, 6ZPR, and 6ZLE). We plan to provide Cpd 3 as a tool compound free of charge as BI-8925 in the course of the Boehringer Ingelheim Open Innovation initiative (https://openmre/molecules/mlkl-bi-8925).

**Acknowledgments.** We thank Claudia Weber, Nicole Ernst, Dominik Frey, Stefanie Gruber, Yvette Hövels, Dominik Raatz, Oliver Wachter, Franziska Moser, and Heike Kölle for expert technical support; Dirk Reinert and Expose GmbH, Villigen for data collection; and the staff at SLS beamlines PXI and PXXII for their continuous support.

1. M. Pasparakis, P. Vandenabeele, Necroptosis and its role in inflammation. Nature 517, 311–320 (2015).
2. D. Vercaemden et al., Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187, 1477–1485 (1998).
3. A. Kaczmarek, P. Vandenabeele, D. V. Krysko, Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209–223 (2013).
4. Y. Ito et al., RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353, 603–608 (2016).
5. P. S. Welz et al., FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nat. Immunol. 472, 330–334 (2017).
6. M. C. Bonnet et al., The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 35, 572–582 (2011).
7. C. Zhuang, F. Chen, Small-molecule inhibitors of necroptosis: Current status and perspectives. J. Med. Chem. 63, 1499–1510 (2019).
8. J. M. Murphy et al., The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443–453 (2013).
9. J. M. Murphy et al., Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. Biochim. J. 457, 369–377 (2014).
10. L. Sun et al., Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).
11. L. Su et al., A plug release mechanism for membrane permeation by MLKL. Structure 22, 1485–1500 (2014).
12. D. E. McNamara et al., Direct activation of human MLKL by a select repertoire of inositol phosphate metabolites. Cell Chem. Biol. 26, 863–877.e7 (2019).
13. H. Wang et al., Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54, 133–146 (2014).
14. J. M. Hildebrand et al., Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 111, 15072–15077 (2014).
15. B. Ma et al., ATP-competitive MLKL binders have no functional impact on necroptosis. Cell 161, 10165783 (2015).
16. L. S. Daehong Liao, W. Liu, H. Sudan, X. Wang, X. Lei, Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein. MedChemComm 5, (2014).
17. B. Yan et al., Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein. Chem. Commun. (Camb.) 53, 3637–3640 (2017).
18. C. M. Dovey et al., MLKL requires the inositol phosphate code to execute necroptosis. Mol. Cell 70, 936–948.e7 (2018).
19. G. Guarato et al., Sequential engagement of distinct MLKL phosphatidylinositol-binding sites executes necroptosis. Mol. Cell 61, 589–601 (2016).
20. Z. Cai et al., Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16, 55–65 (2014).
21. X. Chen et al., Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res. 24, 105–121 (2014).
22. D. Huang et al., The MLKL channel in necroptosis is an octamer formed by tetramers in a dimeric process. Mol. Cell Biol. 37, e00497-16 (2017).
23. D. K. Wilkins et al., Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. Biochemistry 38, 16424–16431 (1999).
24. N. Bansal, S. Sciabola, G. Bhisetti, Understanding allosteric interactions in hMLKL protein that modulate necroptosis and its inhibition. Sci. Rep. 9, 16853 (2019).
25. K. H. Arne et al., Analysis of the N-terminal region of human MLKL, as well as two distinct MLKL isoforms, reveals new insights into necroptotic cell death. Biosci. Rep. 36, e00291 (2015).
26. K. Nilsson, C. Sundström, Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. Int. J. Cancer 13, 808–823 (1974).
27. Z. Zhang et al., "Mlkl inhibitors." World patent WO2018157800A1 (2018).
28. W. Kabsch, XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
29. C. Vonrhein et al., Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293–302 (2011).
30. A. Vagin, A. Teplyakov, Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22–25 (2010).
31. A. J. McCoy et al., Phaser crystallographic software. J. Appl. Cryst. 40, 658–674 (2007).
32. M. D. Winn et al., Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011).
33. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
34. D. Liebschner et al., Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861–877 (2019).
35. B. E. Bricogne et al., BUSTER Version 2.11.7 (Global Phasing Ltd., Cambridge, UK, 2017).
36. M. Sattler, J. Schleucher, C. Griesinger, Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients. Prog. Nucl. Magn. Reson. Spectrosc. 34, 93–158 (1999).
37. D. S. Wishart et al., 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 6, 135–140 (1995).
38. C. Zwahlen et al., Methods for measurement of intermolecular NOEs by multinuclear NMR spectroscopy: Application to a bacteriophage λ N-peptide/boxB RNA complex. J. Am. Chem. Soc. 119, 6711–6721 (1997).
39. W. F. Vranken et al., The CCPN data model for NMR spectroscopy: Development of a software pipeline. Proteins 59, 687–696 (2005).
40. Y. Shen, F. Delaglio, G. Cornilescu, A. Bax, TALOS+: A hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J. Biomol. NMR 44, 213–223 (2009).
41. P. Güntert, L. Buchner, Combined automated NOE assignment and structure calculation with CYANA. J. Biomol. NMR 62, 453–471 (2015).
42. S. Yao et al., Measuring translational diffusion of 15N-enriched biomolecules in complex solutions with a simplified 1H-15N HMQC-filtered BEST sequence. Eur. Biophys. J. 47, 891–902 (2018).
43. D. H. Wu, A. Chen, C. S. Johnson Jr, An improved diffusion-ordered spectroscopy experiment incorporating bipolar-gradient pulses. J. Magn. Reson. A 115, 260–264 (1995).
44. M. Liu et al., Improved watergate pulse sequences for solvent suppression in NMR spectroscopy. J. Magn. Reson. 132, 125–129 (1998).